Clinical Research as a Care Option Speakers

Tom Pike

Tom Pike

Former CEO


With more than 30 years of experience, Tom Pike has a combination of global leadership, strategy and operations experience spanning the healthcare industries: pharmaceuticals, payers, and providers as well as technology and services. Most recently, Tom was CEO of the CRO Quintiles Transnational, where he led the company through a successful public offering, helped it grow into the Fortune 500, and in 2016 be awarded one of the world’s Most Ethical Companies. He retired late in 2016 after the merger with IMS Health. At Quintiles he was a frequent public speaker on improving clinical research, leadership, and other topics. Prior to Quintiles Tom was a leader at Accenture and earlier worked with McKinsey and Company.

Tom has studied innovation in pharmaceutical development and believes the current approach and costs are unsustainable.   New therapies have never been more promising. However, given that patients’ lives are at stake and the complexity and failure rate of new medicines is very high, a comprehensive cross industry approach is required to get safe, effective medicines to patients faster and more cost efficiently. He has spoken internationally at forums such as the 2016 Global Bio Conference in Seoul Korea, and in the US at forums such as Tufts Center for Strategic Drug Development and the CNS Summit. An accomplished company spokesperson, Tom has been featured in numerous print and network media appearances including with Maria Bartiromo, Bloomberg News, and as a regular guest of Jim Cramer on Mad Money on CNBC.

In 2015, Tom was named by the AACSB, the global accrediting body and membership association for business schools, as one of the first 100 AACSB Influential Leaders. Tom serves on the Advisory Council for the Schaefer Center, a leading school of public health at University of Southern California and as an advisor to the Samsung Biologics Advisory Board. He also serves on the board of a services start-up company and advises an investment fund.

Return to Speakers page »